Microbix Biosystems (TSX:MBX) ROE %: -22.11% (As of Mar. 2026)


TSX:MBX Microbix Biosystems Inc TSX:MBX
52 GF Score
Price C$0.31
GF Value C$0.24
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Microbix Biosystems ROE %?

Microbix Biosystems TSX:MBX +5.17% 52 ROE % is -22.11% as of Mar. 2026. GuruFocus rates TSX:MBX with a GF Score™ of 52/100 and a GF Value™ of C$0.24 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,255 Biotechnology companies, Microbix Biosystems ranks better than 61.43% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Microbix Biosystems's annualized net income for the quarter that ended in Mar. 2026 was C$-5.72 Mil. Microbix Biosystems's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was C$25.87 Mil. Therefore, Microbix Biosystems's annualized ROE % for the quarter that ended in Mar. 2026 was -22.11%.

The historical rank and industry rank for Microbix Biosystems's ROE % or its related term are showing as below:

TSX:MBX' s ROE % Range Over the Past 10 Years
Min: -72.6   Med: 0.08   Max: 25.68
Current: -20.44

During the past 13 years, Microbix Biosystems's highest ROE % was 25.68%. The lowest was -72.60%. And the median was 0.08%.

TSX:MBX's ROE % is ranked better than
61.43% of 1255 companies
in the Biotechnology industry
Industry Median: -38.18 vs TSX:MBX: -20.44

Microbix Biosystems  (TSX:MBX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-5.72/25.8735
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-5.72 / 13.512)*(13.512 / 35.978)*(35.978 / 25.8735)
=Net Margin %*Asset Turnover*Equity Multiplier
=-42.33 %*0.3756*1.3905
=ROA %*Equity Multiplier
=-15.9 %*1.3905
=-22.11 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-5.72/25.8735
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-5.72 / -5.72) * (-5.72 / -5.048) * (-5.048 / 13.512) * (13.512 / 35.978) * (35.978 / 25.8735)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.1331 * -37.36 % * 0.3756 * 1.3905
=-22.11 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Microbix Biosystems ROE % Related Terms


Microbix Biosystems ROE % Historical Data

* Premium members only.

The historical data trend for Microbix Biosystems's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbix Biosystems ROE % Chart

Microbix Biosystems Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.68 8.23 -0.16 13.30 -8.01

Microbix Biosystems Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 -21.77 -20.75 -17.16 -22.11

TSX:MBX vs VRTX, REGN, ALNY: ROE % Comparison

For the Biotechnology subindustry, Microbix Biosystems's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbix Biosystems ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's ROE % distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's ROE % falls into.


TSX:MBX
52GF Score
Microbix Biosystems Inc TSX:MBX
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microbix Biosystems ROE % Calculation

Microbix Biosystems's annualized ROE % for the fiscal year that ended in Sep. 2025 is calculated as

ROE %=Net Income (A: Sep. 2025 )/( (Total Stockholders Equity (A: Sep. 2024 )+Total Stockholders Equity (A: Sep. 2025 ))/ count )
=-2.246/( (28.297+27.788)/ 2 )
=-2.246/28.0425
=-8.01 %

Microbix Biosystems's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-5.72/( (26.607+25.14)/ 2 )
=-5.72/25.8735
=-22.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -22.11% mean?
Microbix Biosystems (TSX:MBX) has a ROE % of -22.11% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Microbix Biosystems and its competitors. According to the industry distribution chart, Microbix Biosystems ranks #484 out of 1255 companies in the Biotechnology industry, placing it in the top 38.6%.
Is Microbix Biosystems' ROE % too high?
Microbix Biosystems' current ROE % is -22.11%. Based on the distribution chart, Microbix Biosystems ranks #484 out of 1255 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Microbix Biosystems has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #484 out of 1255 companies for ROE %. This puts Microbix Biosystems in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current ROE % is -22.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (TSX:MBX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.24, compared to a current price of C$0.31 — trading 27.1% above its estimated fair value. The current ROE % is -22.11%. Microbix Biosystems' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Microbix Biosystems (TSX:MBX), the current ROE % is -22.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microbix Biosystems (TSX:MBX) Overvalued in 2026?

Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued. The current stock price of C$0.31 is trading 27.1% above its estimated GF Value™ of C$0.24. GuruFocus considers Microbix Biosystems to be Modestly Overvalued.

Key valuation signals for TSX:MBX:

  • ROE %: -22.11%
  • GF Value™: C$0.24 vs. price of C$0.31 (27.1% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the TSX:MBX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Microbix Biosystems Business Description

Other Exchanges MBXBF:USA
Address 265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
52GF Score

Get the complete analysis for TSX:MBX

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.31
Price
C$0.24
GF Value